Clover Health InvestmentsCLOV
CLOV
About: Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Employees: 570
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more call options, than puts
Call options by funds: $21M | Put options by funds: $10.5M
96% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 27
30% more capital invested
Capital invested by funds: $293M [Q4 2024] → $380M (+$87M) [Q1 2025]
12% more funds holding
Funds holding: 176 [Q4 2024] → 197 (+21) [Q1 2025]
2.73% more ownership
Funds ownership: 22.55% [Q4 2024] → 25.28% (+2.73%) [Q1 2025]
16% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 56
Research analyst outlook
We haven’t received any recent analyst ratings for CLOV.
Financial journalist opinion
Positive
Zacks Investment Research
1 month ago
All You Need to Know About Clover Health Investments (CLOV) Rating Upgrade to Strong Buy
Clover Health Investments (CLOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Positive
Seeking Alpha
1 month ago
Clover Health: Stars Are Aligning For GAAP Profitability In FY 2026
Clover reported impressive Q1 earnings with robust topline growth and improving profitability metrics thanks to a 30% YoY increase in its member base. Clover could see $95 million in additional revenues in FY 2026 without any member growth as a result of CMS increasing MA payouts by 5.1%. With Clover set to be eligible for a 5% quality bonus in 2026 thanks to its 4-star rating, I expect it to reach GAAP profitability in FY 2026.
Negative
Benzinga
1 month ago
Top 3 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 8, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Positive
Zacks Investment Research
1 month ago
CLOV Stock Rises as Q1 Earnings Beat Estimates, Revenues Up Y/Y
Clover Health's first-quarter 2025 results continue to benefit from the strength of its strong member retention. A decline in operating loss bodes well.
Neutral
Seeking Alpha
1 month ago
Clover Health Investments, Corp. (CLOV) Q1 2025 Earnings Call Transcript
Clover Health Investments, Corp. (NASDAQ:CLOV ) Q1 2025 Earnings Conference Call May 6, 2025 5:00 PM ET Company Participants Ryan Schmidt - Investor Relations Andrew Toy - Chief Executive Officer Peter Kuipers - Chief Financial Officer Conference Call Participants Jonathan Yong - UBS Matt Hewitt - Craig-Hallum Capital Richard Close - Canaccord Genuity Operator Ladies and gentlemen, good afternoon and welcome to the Clover Health First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
1 month ago
Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates
Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of $0.05 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-year First quarter 2025 Total revenues of $462 million, up 33% year-over-year Medicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management model Meaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year ago Adjusted EBITDA of $26 million, up 279% year-over-year Adjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpoint Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpoint Adjusted EBITDA profitability between $50 million and $70 million Adjusted Net income between $50 million and $70 million WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2025.
Positive
Zacks Investment Research
1 month ago
Watch These 3 MedTech Stocks for Q1 Earnings: Beat or Miss?
MedTech companies' quarterly results are likely to reflect strength in customer demand. Let's see how FMS, MASI and CLOV are placed ahead of their earnings releases.
Neutral
GlobeNewsWire
1 month ago
Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure
New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions (25% lower) in heart failure patients New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions (25% lower) in heart failure patients
Neutral
GlobeNewsWire
1 month ago
Clover Health Announces Changes to Board of Directors
Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders' Meeting Thomas L. Tran will become Chairman of the Audit Committee and the Nominating and Corporate Governance Committee, and Lee A. Shapiro will not stand for re-election at the 2025 Annual Shareholders' Meeting
Charts implemented using Lightweight Charts™